Obiettive To study the efficacy and safety of monochromatic excimer light (MEL) on 37 vitiligo patients referred to our clinico Methods In a pilot study, 37 patients (17 males, 20 females) with acrofacial (n = 21), focal (n =11), segmental (n = 1), and generalized (n = 4) vitiligo were treated twice weekly with MEL far a maximum period of 6 months. Results Thirty-five patients (95%) showed signs of repigmentation within the first eight treatments. The treatment resulted in good repigmentation in 16 patients, and excellent repigmentation in 18 patients. Adverse events were limited to transient erythema. In addition, some patients (n = 3) not responding to prior narrow-band UVE (NH UVE) phototherapy showed good results with MEL in our series. Conclusions Treatment with 308 nm MEL far vitiligo may be more effective in ob.taining rapid repigmentation than phototherapy with NH UVE. The results in this study afe similar to those recently reported with a 308 nm excimer laser, but 308 MEL could present some advantages: the possibility of treating larger areas compared to the 308 nm excimer laser, with shorter treatment times and better patient compliance. The overall good results and the early appearance of repigmentation contribute to reducing the cumulative exposure to UV radiation. Key words: monochromatic excimer light, narrow-band UVB, vitiligo Received: 24 September 2002, accepted 18 December 2002 Vitiligo is a common idiopathic acquired depigmentation disorder,l affecting 1-2% of the world population with no predilection for age, sex or racial background, caused by selective destruction of melanocytes. The disease is characterized by circumscribed white spots on the skin tending to enlarge centrifugally over time or, less frequentiy, to recover spontaneously at least in part.2
therapy, has been described in the treatment of recalcitrant palmoplantar psoriasis.-z3; 24 The monochromatic excimer light (308 nm MEL) may present some advantages over the laser: lower power density and consequentiy reduced risk of accidents due to overexposure; larger irradiation field with the possibility to treat larger areas at a time, with shorter treatment duration.
The aim of our pilot study was to investigate the effectiveness of this new source in the treatment of vitiligo. We have conducted a pilot open trial with MEL on 37 vitiligo patients referring to our clinico Our results suggest that the 308 nm MEL may represent a new therapeutic option for the management of vitiligo that may result in repigmentation of vitiligo lesions in a shorter rime as compared with current modalities.
Materials and methods
The source was a 308-nm XeCl MEL device (EXCILITE(8)-DEKA MELA, Plorence, Italy). It produces a power density of 48 mW/cm2 at a distance of 15 cm from skin and, at this fixed distance, the irradiation field covers an area of 504 cm2. This areahas a rectanguiar shape (36 cm x 14 cm). Thedevicecan be seen in fig. 1 . A template with a series of holes and a shutter can be adapted on the device for the MED determination. Ali patients were phototested on normally pigmented skin with 308 nm MEL prior to treatment. Por MED determination a series of five increasing exposures, with 25% progression, was administered on the midback.
Ali 37 patients were treated with MEL as monotherapy from March 2002 to September 2002. Therapy was adrninistered twice a week, on non-consecutive days.
The initial tluence for each patient was 70% of the MED. Dose increments at every other treatment were: 40% from treatment 1 to 4; 30% from treatment 4 to 8; 20% constantly from treatment 8 onwards. The dose was held constant when minimal asyrnptomatic erythema occurred in the lesions. If involved. 13 The goal of phototherapy is to stimulate melanocytes present in the adjacent area to migrate and repopulate the vitiliginous areas. Until a few years ago, PUVA therapy was the most popular treatment far vitiligo worldwide. Synthetic compounds such as 8-methoxypsoralen (8-MOP), 5-methoxypsoralen (5-MOP) and trimethylpsoralen (TMP) afe used in modero photochemotherapy regimens in the form of topical agents (creams, gels and solutions) or orally, followed by exposure to natural sunlight (so-cal1edPUVASOL) orto artificial UVA radiation (PUVA). Topical PUVA has to be dalle cautiously to avoid phototoxicity and koebnerization (appearance of new lesions at blistered sites). Table l .
Patients who had had stable disease affecting no more than 20% body surface and recent onset of the disease (less than 5 years duration) were eligible for the study. Thirtyseven patients (17 men, 20 women) were included in the study.
symptomatic erythema (burning, pain) or blistering developed, treatment was omitted (once or twice) , and when treatment was resumed the last dose was decreased by 20%. Treatments were performed by a physician. Once 75% repigmentation was achieved, the frequency of treatments was tapered to once a week until complete repigmentation was achieved or until the protocol (6 months) was completed.
No topical treatment was applied to vitiligo areas during the treatment with 308 nm MEL. When the face was irradiated the eyes were protected by UV-blocking goggles. In the case of vitiligo on the eyelids and in the orbital area, patients were instructed to keep their eyes shut during the treatments.
Unaffected skin inside the irradiation field was shielded with surgical tape or with a high SPF sunscreen applied prior to treatment to avoid unnecessary exposure and hyperpigmentation. The ages of the patients ranged from 15 to 54 years (median 34 years). Twenty-two of the 37 patients had skin phototype III, and the remaining 15 patients had skin phototype IV. The MED on unaffected skin, determined with the MEL device, as described earlier, ranged from 0.4 J/cm2 in skin type III to a maximum of 1.25 J/cm2 in skin type IV. Disease duration ranged from 2 months to 5 years.
Lesional photography was performed at the initial pretreatment visit, then monthly thereafter, and also when initial repigmentation first appeared. fig. 3 Same patient after eight treatments: almost complete repigmentation.
Assessment of treatment efficacy
Repigmentation was graded according to the percentage of repigmentation in the treated area: this was evaluated by two independent observers who compared photographs.
The response to treatment was expressed as 'no repigmentation' (score O), 'poor repigmentation' (between 1% and 25%, score 1), 'moderate repigmentation' (between 26% and 50%, score 2), 'good repigmentation' (between 51% and 75%, score 3), and 'excellent repigmentation' (more than 75%, score 4).
In most of the patients vitiligo was localized to more than one gite, so only 'overall' repigmentation grade was considered and not repigmentation grade related to the treated areas.
Patients that showed less than 25% repigmentation or did not respond at ali after 3 months were excluded from the study.
Informed written consent was obtained from the patients. All patients received a phototherapy information sheet. The study was approved by the Ethical Committee of the Institute. In 35 patients (95%) repigmentation began within the first eight sessions (Table 1) . Thirty-six patients bave completed the study. Only one patient did not respond to treatment and was excluded from the study after 3 months: the patient had generalized vitiligo, had already been treated with NB UVB, and the areas selected far treatment were the hands.
Certain anatomical sites responded better than others.
Response rates based on vitiligo lesion sites afe given in Table 3 .
The best response was achieved with lesions located on the face, neck and trunk. Lesions located on the abdomen, back, arms
Results
Thirty-three patients (89%) obtained an acceptable degree of repigmentation after 3 months; 21 (57%) of these patients achieved 'good repigmentation' and 12 (32%) achieved 'excellent repigmentation'. At the end of the evaluation period the number ofpatients with grade 4 repigmentation increased to 18 (49%).
In the 'excellent repigmentation' group, two patients bave achieved complete repigmentation after 3 months and consequentiy the treatment was stopped: one patient had sparse lesions on the forehead (figs 2 and 3) and the other patient had sparse lesions on bolli legs.
Distribution of patients on the basis of the degree of repigmentation obtained can be seen in 
Discussion
The recent report by Spencer et al.22 has shown some advantages of targeted phototherapy with the 308 nm excimer laser: the rapidity of onset of repigmentation, the good overall response in terms of repigmented area, and the lower number oftreatments needed to achieve satisfactory repigmentation compared with conventional NB UVB. Another important point is the possibility of selectively irradiating vitiligo patches without the involvement of the neighbouring healthy skin.
Nevertheless the authors bave indicated that the major drawback may be the very small area of the irradiation field (2 x 2 cm) and consequently the lengthy treatment times in the case of larger lesions.
With 308 nm MEL we noted an early appearance of repigmentation in the majority of patients (35 patients) -between treatments 4 and 8 (Table 1) . This finding is similar to that described with the 308-nm excimer laser. In addition, in patients that did not respond to prior treatment with NB UVB, pigmentation appeared between treatments 5 and 7, except in
ODe patient who did not respond to treatment. Table 2 shows that 12 patients (32%) experienced excellent repigmentation and 21 patients (57%) good repigmentation after only 3 months of treatment. An interesting finding is that after 6 months the results do not show striking differences: only six patients move from score 3 to score 4. This finding demonstrates that when patients do respond to the treatment they respond at the beginning; otherwise they do not respond at ali.
This seems peculiar to this kind of treatment and is not always the case for conventional treatment with NB UVB, at least in our experience. In conventional NB UVB it is not uncommon to see a patient responding to treatment after 3 or 4 months, even if after the first treatments hardly any pigmentation was seen.
The percentage of patients achieving grade 4 repigmentation after 3 months in this study (49%) is higher than that described in the firststudyon the efficacyofNB UVB. 16 In that subset, 8% of patients repigmented more than 75% after 3 months of treatment and 63% did so after 12 months. Our results afe more similar to those described in recent reports on the use of NB UVB in adults17 and in children. 
